KLK3 and prostate carcinoma: This data calls attention for the kinetics of PSA, genetic differences among the prostate cancer cells and the use of refined imaging tests like PSMA-PET during the close follow-up to select adequate treatment volume and dose to SRT at a lower PSA level for these patients.